Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib plus platinum doublet chemotherapy vs osimertinib in EGFR-mutant non-squamous NSCLC with brain metastases
CTR20242992Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in Non-small cell lung cancer (NS-NSCLC), brain metastases, sponsored by Allist Pharmaceuticals. Started Sep 2024; status: active.
02
Drugs
furmonertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)brain metastases
Beyond the preview
Go deeper on CTR20242992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242992.